These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28912774)

  • 1. Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.
    Schmitt C; Marie-Cardine A; Bensussan A
    Front Immunol; 2017; 8():1010. PubMed ID: 28912774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease.
    Shaw J; Kollnberger S
    Front Immunol; 2012; 3():339. PubMed ID: 23162554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
    Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.
    Ortonne N; Le Gouvello S; Tabak R; Marie-Cardine A; Setiao J; Berrehar F; Nghe-Tang A; Martin N; Bagot M; Bensussan A
    Exp Dermatol; 2012 Jun; 21(6):461-3. PubMed ID: 22621189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Bagot M
    Indian J Dermatol; 2017; 62(2):142-145. PubMed ID: 28400633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2.
    Sivori S; Falco M; Carlomagno S; Romeo E; Soldani C; Bensussan A; Viola A; Moretta L; Moretta A
    Blood; 2010 Sep; 116(10):1637-47. PubMed ID: 20147700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09.
    Cauli A; Shaw J; Giles J; Hatano H; Rysnik O; Payeli S; McHugh K; Dessole G; Porru G; Desogus E; Fiedler S; Hölper S; Carette A; Blanco-Gelaz MA; Vacca A; Piga M; Ibba V; Garau P; La Nasa G; López-Larrea C; Mathieu A; Renner C; Bowness P; Kollnberger S
    Rheumatology (Oxford); 2013 Nov; 52(11):1952-62. PubMed ID: 23804219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killer-cell immunoglobulin-like receptors (KIR) and HLA-class I heavy chains in ankylosing spondylitis.
    Cauli A; Piga M; Dessole G; Porru G; Floris A; Vacca A; Desogus E; La Nasa G; Mathieu A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S15-9. PubMed ID: 25381967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis.
    Chan AT; Kollnberger SD; Wedderburn LR; Bowness P
    Arthritis Rheum; 2005 Nov; 52(11):3586-95. PubMed ID: 16255049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis.
    Wong-Baeza I; Ridley A; Shaw J; Hatano H; Rysnik O; McHugh K; Piper C; Brackenbridge S; Fernandes R; Chan A; Bowness P; Kollnberger S
    J Immunol; 2013 Apr; 190(7):3216-24. PubMed ID: 23440420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
    Marie-Cardine A; Viaud N; Thonnart N; Joly R; Chanteux S; Gauthier L; Bonnafous C; Rossi B; Bléry M; Paturel C; Bensussan A; Bagot M; Sicard H
    Cancer Res; 2014 Nov; 74(21):6060-70. PubMed ID: 25361998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abundant CpG-sequences in human genomes inhibit KIR3DL2-expressing NK cells.
    Pugh J; Guethlein L; Parham P
    PeerJ; 2021; 9():e12258. PubMed ID: 34760351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation-Induced Killer Cell Immunoglobulin-like Receptor 3DL2 Binding to HLA-B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis.
    Ridley A; Hatano H; Wong-Baeza I; Shaw J; Matthews KK; Al-Mossawi H; Ladell K; Price DA; Bowness P; Kollnberger S
    Arthritis Rheumatol; 2016 Apr; 68(4):901-14. PubMed ID: 26841353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of HLA-Class I Heavy-Chain Interactions with Killer-Cell Immunoglobulin-Like Receptors in Immune Regulation.
    Kollnberger S
    Crit Rev Immunol; 2016; 36(3):269-282. PubMed ID: 28008807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific.
    Hansasuta P; Dong T; Thananchai H; Weekes M; Willberg C; Aldemir H; Rowland-Jones S; Braud VM
    Eur J Immunol; 2004 Jun; 34(6):1673-9. PubMed ID: 15162437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.